Prayagraj: The health department teams has identified 8 blocks of the district, including Ram Nagar, Meja, Kotwa, Kaudhiyara, Dhanupur, Soraon, Bahari.

Review Article Published: November 2009 The bladder extracellular matrix. Part I: architecture, development and disease Karen J. Aitken & Darius J. Bägli Nature Reviews Urology 6, 596–611 (2009 ...

Even so, 30% of people with bladder cancer have no identifiable risk. Fortunately for you, a noninvasive cancer was found that was less than 3 cm, which is the best possible result for bladder cancer.

The U.S. Food and Drug Administration has approved UGN-102 (mitomycin intravesical solution) for the treatment of adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder ...

Prostate and bladder cancer in men can be prevented with the right lifestyle practices. Around Father's Day 2025 is a good time to learn such tips. Father's day 2025: Father’s Day, celebrated ...

What's Your Diagnosis Published: April 2004 Diagnosis: Filariasis Thomas M. Donnelly DVM Lab Animal 33, 20–21 (2004) Cite this article ...

LOS ANGELES, CA– In a groundbreaking achievement set to reshape the future of transplant medicine, Dr. Inderbir S. Gill has led the world’s first successful bladder transplant in a human being ...

Ultimately, the convenience of peeing in the shower doesn’t outweigh the cumulative toll it can take on your bladder, pelvic floor, and overall hygiene. Sitting down, taking an extra minute ...

Conventional bladder tumors did not have these cells. The HV tumors also had a protein, TM4SF1, on the surface of their cells.

The disease, a type of non-muscle invasive bladder cancer, affects about 82,000 people in the U.S. each year, with around 59,000 experiencing a recurrence, according to UroGen.

Despite a recent rebuff from an FDA advisory committee, the first treatment for a specific and underserved cohort of U.S. bladder cancer patients has crossed the FDA finish line as UroGen Pharma ...

Yang, H., et al. (2025). Bladder cancer variants share aggressive features including a CA125+ cell state and targetable TM4SF1 expression. Nature Communications. doi.org/10.1038/s41467-025-59888-8.